New guidelines on cardiovascular diseases and the results of clinical research: Review of European Cardiology Congress 2018

Elena V. Frolova

doi:10.17816/RFD2019127-34

Russian Family Doctor ›› 2019, Vol. 23 ›› Issue (1) : 27 -34. DOI: 10.17816/RFD2019127-34

Articles

oration

New guidelines on cardiovascular diseases and the results of clinical research: Review of European Cardiology Congress 2018

Elena V. Frolova

Author information +

History +

PDF

Abstract

In this review the information is presented about new clinical guidelines on arterial hypertension, syncope guidelines, about screening of atrial fibrillation and antithrombotic and anticoagulants usage according clinical trials data. Attention is payed to digital technologies in health care sector. This information is based on data of European Cardiology Congress 2018.

Keywords

arterial hypertension / digital health technologies / antithrombotic / anticoagulants / atrial fibrillation

Cite this article

Download citation ▾

Elena V. Frolova. New guidelines on cardiovascular diseases and the results of clinical research: Review of European Cardiology Congress 2018. Russian Family Doctor, 2019, 23(1): 27-34 DOI:10.17816/RFD2019127-34

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. https://doi.org/10.1093/eurheartj/ehy339.

[2]

Виллевальде С.В., Котовская Ю.В., Орлова Я.А. Рекомендации по ведению артериальной гипертонии Европейского общества кардиологов и Европейского общества по артериальной гипертонии 2018 года. 2018. [Villeval’de SV, Kotovskaya YV, Orlova YA. Rekomendatsii po vedeniyu arterial’noy gipertonii Evropeyskogo obshchestva kardiologov i Evropeyskogo obshchestva po arterial’noy gipertonii 2018 goda. 2018. (In Russ.)]

[3]	Brignole M, Moya A, de Lange FJ, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39(21):1883-1948. https://doi.org/10.1093/eurheartj/ehy037.

[4]

Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036-1046. https://doi.org/10.1016/s0140-6736(18)31924-x.

[5]	The ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018;379(16):1529-1539. https://doi.org/10.1056/NEJMoa1804988.

[6]	Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-1393. https://doi.org/10.1093/eurheartj/ehy136.

[7]	Steinhubl SR, Waalen J, Edwards AM, et al. Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial. JAMA. 2018;320(2):146-155. https://doi.org/10.1001/jama.2018.8102.

[8]	Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. Circulation. 2013;127(8):930-937. https://doi.org/10.1161/CIRCULATIONAHA.112.126656.